Moreover, by expressing 597 sequence-validated kinase open reading frame (ORF) in A375 melanoma cell lines harboring B-Raf mutation, treatment with the MAPK agonist PLX4723 activated ERK primarily through a MEK-dependent mechanism without Raf signaling, and therefore facilitated de novo Raf inhibitor resistance [73]. Here, BRAF is linked to melanoma.